Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ratings.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Bristol Myers Squibb, Merck & Company, and GE Healthcare Technologies continue advancing the cancer care ecosystem through ...

While MRK stock looks promising, investing in a single stock can be risky. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of over the ...

MRK stock, with -14% returns since the beginning of 2024, has underperformed the S&P 500 index, up 27%. Merck’s HPV vaccine – Gardasil – is facing a challenge in China amid lower demand.